Institution
University of Hawaii at Manoa
Education•Honolulu, Hawaii, United States•
About: University of Hawaii at Manoa is a education organization based out in Honolulu, Hawaii, United States. It is known for research contribution in the topics: Population & Sea surface temperature. The organization has 13693 authors who have published 25161 publications receiving 1023924 citations.
Papers published on a yearly basis
Papers
More filters
••
University of Melbourne1, University of Queensland2, Mayo Clinic3, University of Colorado Denver4, Flinders University5, Cancer Council Victoria6, Royal Melbourne Hospital7, University of Western Australia8, Auckland City Hospital9, University of Toronto10, University of Southern California11, Cancer Care Ontario12, University of Hawaii at Manoa13, Fred Hutchinson Cancer Research Center14
TL;DR: It was confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of cancers, including some cancers not previously recognized as being a result of MMR mutations, and found no evidence of an increase risk of cancer for their noncarrier relatives.
Abstract: Purpose To determine whether cancer risks for carriers and noncarriers from families with a mismatch repair (MMR) gene mutation are increased above the risks of the general population. Patients and Methods We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1, n 161; MSH2 ,n 222; MSH6 ,n 47; and PMS2 ,n 16) and 1,029 their unaffected relatives who did not carry a mutation every 5 years at recruitment centers of the Colon Cancer Family Registry. For comparison of cancer risk with the general population, we estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers. Results Over a median follow-up of 5 years, mutation carriers had an increased risk of colorectal cancer (CRC; SIR, 20.48; 95% CI, 11.71 to 33.27; P .001), endometrial cancer (SIR, 30.62; 95% CI, 11.24 to 66.64; P .001), ovarian cancer (SIR, 18.81; 95% CI, 3.88 to 54.95; P .001), renal cancer (SIR, 11.22; 95% CI, 2.31 to 32.79; P .001), pancreatic cancer (SIR, 10.68; 95% CI, 2.68 to 47.70; P .001), gastric cancer (SIR, 9.78; 95% CI, 1.18 to 35.30; P .009), urinary bladder cancer (SIR, 9.51; 95% CI, 1.15 to 34.37; P .009), and female breast cancer (SIR, 3.95; 95% CI, 1.59 to 8.13; P .001). We found no evidence of their noncarrier relatives having an increased risk of any cancer, including CRC (SIR, 1.02; 95% CI, 0.33 to 2.39; P .97). Conclusion We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of cancers, including some cancers not previously recognized as being a result of MMR mutations, and found no evidence of an increased risk of cancer for their noncarrier relatives. J Clin Oncol 30:958-964. © 2012 by American Society of Clinical Oncology
298 citations
••
TL;DR: In this paper, three parameters are proposed to determine the relative extent of alteration in CM chondrites: the mineralogic alteration index monitors the relative progress of coupled substitutions in the progressive alteration of cronstedtite to Mg-serpentine and increases with increasing alteration.
297 citations
••
TL;DR: There are massive content omissions presently but it feels that Google Scholar will become an excellent free tool for scholarly information discovery and retrieval with future changes in its structure.
Abstract: Purpose – To identify the pros and the cons of Google Scholar.Design/methodology/approach – Chronicles the recent history of the Google Scholar search engine from its inception in November 2004 and critiques it with regard to its merits and demerits.Findings – Feels that there are massive content omissions presently but that, with future changes in its structure, Google Scholar will become an excellent free tool for scholarly information discovery and retrieval.Originality/value – Presents a useful analysis for potential users of the Google Scholar site.
296 citations
••
TL;DR: SylA defines a new class of proteasome inhibitors that includes glidobactin A (GlbA), a structurally related compound from an unknown species of the order Burkholderiales, for which it is shown that SylA irreversibly inhibits all three catalytic activities of eukaryotic proteasomes, thus adding prote asome inhibition to the repertoire of modes of action of virulence factors.
Abstract: Pathogenic bacteria often use effector molecules to increase virulence. In most cases, the mode of action of effectors remains unknown. Strains of Pseudomonas syringae pv. syringae (Pss) secrete syringolin A (SylA), a product of a mixed non-ribosomal peptide/polyketide synthetase, in planta1. Here we identify SylA as a virulence factor because a SylA-negative mutant in Pss strain B728a obtained by gene disruption was markedly less virulent on its host, Phaseolus vulgaris (bean). We show that SylA irreversibly inhibits all three catalytic activities of eukaryotic proteasomes, thus adding proteasome inhibition to the repertoire of modes of action of virulence factors. The crystal structure of the yeast proteasome in complex with SylA revealed a novel mechanism of covalent binding to the catalytic subunits. Thus, SylA defines a new class of proteasome inhibitors that includes glidobactin A (GlbA), a structurally related compound from an unknown species of the order Burkholderiales2, for which we demonstrate a similar proteasome inhibition mechanism. As proteasome inhibitors are a promising class of anti-tumour agents, the discovery of a novel family of inhibitory natural products, which we refer to as syrbactins, may also have implications for the development of anti-cancer drugs3. Homologues of SylA and GlbA synthetase genes are found in some other pathogenic bacteria, including the human pathogen Burkholderia pseudomallei, the causative agent of melioidosis4. It is thus possible that these bacteria are capable of producing proteasome inhibitors of the syrbactin class.
296 citations
••
TL;DR: Results suggest that particular patterns of defensive behaviors may provide a very appropriate animal model for the analysis of pharmacological effects on anxiety, with females more defensive than males.
296 citations
Authors
Showing all 13867 results
Name | H-index | Papers | Citations |
---|---|---|---|
Pulickel M. Ajayan | 176 | 1223 | 136241 |
Steven N. Blair | 165 | 879 | 132929 |
Qiang Zhang | 161 | 1137 | 100950 |
Jack M. Guralnik | 148 | 453 | 83701 |
Thomas J. Smith | 140 | 1775 | 113919 |
James A. Richardson | 136 | 363 | 75778 |
Donna Neuberg | 135 | 810 | 72653 |
Jian Zhou | 128 | 3007 | 91402 |
Eric F. Bell | 128 | 631 | 72542 |
Jorge Luis Rodriguez | 128 | 834 | 73567 |
Bin Wang | 126 | 2226 | 74364 |
Nicholas J. Schork | 125 | 587 | 62131 |
Matthew Jones | 125 | 1161 | 96909 |
Anthony F. Jorm | 124 | 798 | 67120 |
Adam G. Riess | 118 | 363 | 117310 |